10-Q: Chicago Atlantic BDC Reports Strong Q2 Growth

Chicago Atlantic BDC, Inc. reported a substantial increase in investment income and net assets for the second quarter and first half of 2025, driven by a significant expansion of its loan portfolio.

Summary

• Total investment income for the six months ended June 30, 2025, increased significantly to approximately $25.0 million, up from $5.8 million for the same period in 2024.
• Net investment income for the six months ended June 30, 2025, surged to approximately $15.3 million, compared to $1.4 million for the six months ended June 30, 2024.
• Net assets resulting from operations for the six months ended June 30, 2025, increased to $16.2 million, up from $1.8 million in the prior year period.
• The investment portfolio's fair value grew to approximately $307.5 million as of June 30, 2025, from $275.2 million at December 31, 2024, primarily due to the Loan Portfolio Acquisition completed on October 1, 2024.
• The company issued 16,605,372 shares of common stock for the Loan Portfolio Acquisition, valued at $219,621,125 as of September 28, 2024.
• As of June 30, 2025, 78.5% of the investment portfolio's fair value was concentrated in the cannabis industry.
• All loan investments were rated Grade 2, indicating performance in line with expectations, with no loans on non-accrual status as of June 30, 2025, or December 31, 2024.
• A new senior secured revolving credit agreement was entered into on February 11, 2025, providing up to $100 million in credit, with $5 million outstanding and $95 million available as of June 30, 2025.
• Unfunded commitments on existing loans increased to $16,185,714 as of June 30, 2025, from $1,250,000 at December 31, 2024.
• Quarterly cash dividends of $0.34 per share were declared for the first and second quarters of 2025, an increase from $0.25 per share in the prior year period.

Sentiment

Score: 8

Explanation: The company demonstrates strong financial performance with significant growth in investment income and net assets, driven by strategic portfolio expansion. The credit quality of the loan book appears robust with all loans performing as expected. The new credit facility provides ample liquidity for future growth. While the stock trades at a discount to NAV, the operational results are highly positive.

Positives

• Significant growth in total investment income and net investment income, indicating strong revenue generation from the expanded portfolio.
• Substantial increase in the fair value of the investment portfolio, reflecting successful integration of the Loan Portfolio Acquisition.
• All portfolio loans are performing as expected (Grade 2), with no non-accrual status, demonstrating strong credit quality and effective risk management.
• Establishment of a new $100 million revolving credit facility enhances liquidity and provides capital for future investments.
• Increased quarterly dividend to $0.34 per share signals confidence in sustained earnings and commitment to shareholder returns.
• Voluntary waiver of $658,477 in general and administrative expenses by the Adviser for the six months ended June 30, 2025, and an expense limitation agreement, help manage operating costs.

Negatives

• Cash and cash equivalents decreased to $13.8 million from $23.9 million, reflecting capital deployment into investments.
• Total liabilities increased significantly to $29.9 million from $8.4 million, primarily due to payables for investments purchased, distributions, and the new revolving line of credit.
• Operating expenses increased in dollar terms, though partially offset by waivers and expense limitation agreements.
• The common stock traded at a significant discount to its net asset value per share, with a 21.32% discount as of August 13, 2025.

Risks

• The cannabis industry is highly speculative and subject to legality issues under U.S. federal law, which could impact portfolio companies' ability to operate and result in loan losses.
• Changes in U.S. Presidential administration policies or federal enforcement regarding cannabis could negatively affect portfolio companies.
• U.S. federal courts may refuse to enforce contracts related to cannabis businesses, even if operating legally under state law.
• Assets collateralizing cannabis loans may be forfeited to the U.S. federal government in enforcement actions.
• Potential U.S. Food and Drug Administration regulation of cannabis could adversely affect the industry.
• Difficulty for cannabis businesses to obtain necessary insurance policies exposes the company and its portfolio to additional risks.
• Opposition from other industries (pharmaceutical, adult beverage, tobacco) with powerful lobbying resources could negatively impact the cannabis industry.
• Challenges in accessing traditional banking services and obtaining financing for cannabis companies due to federal uncertainties.
• Evolving and broad cannabis laws and regulations may restrict property use or require additional regulatory approvals.
• Concentration risk exists with three portfolio companies representing 39.5% of fair value and the largest representing 16.8% as of June 30, 2025.
• Credit risk from potential default or non-performance by portfolio companies, especially those with below investment grade securities.
• Interest rate risk due to changes in benchmark rates (PRIME, SOFR) affecting net investment income, particularly with floating-rate debt.
• Prepayment risk, where favorable market conditions could lead to early loan repayments, potentially reducing achievable yields if capital cannot be reinvested at similar rates.
• Risks associated with the new senior secured revolving credit facility, including pledging significant assets as collateral and potential foreclosure if obligations are defaulted upon.

Future Outlook

The company's investment objective is to maximize risk-adjusted returns on equity for shareholders by generating current income from debt investments and capital appreciation from equity and equity-related investments. It intends to continue investing primarily in secured debt, unsecured debt, equity warrants, and direct equity investments in privately held businesses, with a focus on highly complex and regulated industries, particularly the cannabis ecosystem. The company has an active pipeline of approximately $780.3 million in potential investments.

Management Comments

• Our business model is focused primarily on the direct origination of investments through portfolio companies or their financial sponsors.
• We believe that our ability to leverage the existing investment management platform of Chicago Atlantic enables us to operate more efficiently and with lower overhead costs than other funds of comparable size.
• We have an active pipeline of investments and are currently reviewing approximately $780.3 million of potential investments in varying stages of underwriting.

Industry Context

The company operates as a specialty finance firm, focusing on providing capital to industries typically underserved by traditional lenders due to their complexity or regulatory environment, such as the cannabis sector. This niche allows the company to secure attractive pricing, favorable terms, and strong covenants on its debt investments. The BDC structure enables it to pass through significant income to shareholders, while its external management model aims for operational efficiency. The high interest rates on its loans reflect the higher risk and limited capital access in these specialized markets.

Comparison to Industry Standards

• The company's focus on 'highly complex and highly regulated industries typically underserved by other capital providers' allows it to achieve higher 'all-in rates' on its term loans and senior secured notes (ranging from 10.57% to 20.25%) compared to more traditional lending markets.
• The ability to extract 'lender-friendly terms and covenants' and maintain 'low debt to enterprise value' ratios in its portfolio companies, particularly in the esoteric and asset-based lending sub-strategy, suggests a strong risk-mitigation approach within its specialized market.
• The consistent 'Grade 2' investment risk rating across its entire portfolio, indicating performance in-line with expectations and no non-accrual loans, suggests a robust underwriting and monitoring process, which is critical given the inherent risks of its target industries like cannabis.

Legal Proceedings

• No material legal matters or litigation pending as of June 30, 2025.

Related Party Transactions

• The company pays a base management fee of 1.75% of average gross assets and an incentive fee (20% of Pre-Incentive Fee Net Investment Income, subject to a 1.75% quarterly hurdle, and 20% of realized capital gains) to Chicago Atlantic BDC Advisers, LLC (the Adviser).
• The Adviser voluntarily waived $658,477 of general and administrative expenses for the six months ended June 30, 2025, which are not subject to recoupment.
• An expense limitation agreement caps operating expenses (excluding certain fees) at an annualized rate of 2.15% of net assets through September 30, 2025, resulting in $1,107,783 in waivers for the six months ended June 30, 2025.
• The company reimburses the Adviser for costs and expenses incurred in performing administrative obligations, including an allocable portion of compensation for the Chief Compliance Officer and Chief Financial Officer.
• Chicago Atlantic Admin, LLC, a wholly-owned subsidiary of Chicago Atlantic Group, LP, serves as a loan administrator and collateral agent for certain loans, handling collections and disbursements.
• The company co-invests with other investment vehicles managed by its affiliates, with $264.5 million of investments being co-investments as of June 30, 2025.
• The Adviser, as the seed investor, may sell its common stock holdings or distribute them to its members, potentially through a Rule 10b5-1 trading plan.

Stakeholder Impact

• Shareholders benefit from increased net investment income and a higher quarterly dividend of $0.34 per share.
• Shareholders are impacted by the common stock trading at a significant discount (21.32% as of August 13, 2025) to its net asset value.
• Portfolio companies gain access to capital through the company's debt investments, particularly in underserved industries like cannabis, with terms reflecting the unique market conditions.
• Employees (specifically the CCO and CFO and their staff) have a portion of their compensation allocable to the company reimbursed by the Adviser.
• Creditors of the new revolving credit facility benefit from significant assets pledged as collateral.

Next Steps

• Fund unfunded commitments on existing loans, which total $16,185,714 as of June 30, 2025.
• Continue to review and potentially invest in the active pipeline of approximately $780.3 million in potential investments.
• Pay a cash dividend of $0.34 per share on October 10, 2025, to stockholders of record on September 29, 2025.

Key Dates

Recommendation

The company demonstrates robust financial performance with substantial growth in investment income and net assets, driven by strategic portfolio expansion and effective management of its specialized lending activities. The credit quality of the loan portfolio is strong, with all loans performing as expected and no non-accrual status. The new $100 million revolving credit facility provides significant liquidity for continued growth. The increased quarterly dividend signals management's confidence in future earnings. While the stock currently trades at a notable discount to its net asset value, the underlying operational strength and growth trajectory suggest a compelling investment opportunity for long-term investors seeking income and capital appreciation in a unique market segment.

Keywords

Chicago Atlantic BDC, LIEN, Business Development Company, BDC, Cannabis Investment, Secured Debt, Loan Portfolio, Financial Services, Investment Management, SEC Filing, Quarterly Report, Direct Lending, Private Credit